Skip to content

Pyrimethamine

Dihydrofolate Reductase Inhibitor Antimalarial — ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS

Also known as: chloridin, chloridine, diaminopyritamin, pirimecidan, pirimetamin, pyrimethamin

OfpFDA approvedATC P01BD01ATC P01BD51ATC P01BF04

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Pyrimethamine is an ofp drug in the Dihydrofolate Reductase Inhibitor Antimalarial class catalogued in DrugCentral. It was first approved by the FDA in 1953. Its mechanism of action is classified as Dihydrofolate Reductase Inhibitors. DrugCentral lists 23 molecular targets, including Bifunctional dihydrofolate reductase-thymidylate synthase, Bifunctional dihydrofolate reductase-thymidylate synthase and dfrA17. Recorded indications include Chloroquine Resistant Plasmodium Falciparum Malaria, Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention, Encephalitis due to Toxoplasmosis and Malaria.

  • Approval status: ofp (first approved 1953 by the FDA).
  • Drug class: Dihydrofolate Reductase Inhibitor Antimalarial.
  • Mechanism of action: Dihydrofolate Reductase Inhibitors.
  • Molecular targets: Bifunctional dihydrofolate reductase-thymidylate synthase, Bifunctional dihydrofolate reductase-thymidylate synthase, dfrA17 and folA (23 listed in DrugCentral).
  • Indications: Chloroquine Resistant Plasmodium Falciparum Malaria, Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention, Encephalitis due to Toxoplasmosis, Malaria and Toxoplasmosis and others.
  • ATC code: P01BD01 (Diaminopyrimidines).
  • Molecular formula: C12H13ClN4; molecular weight 248.71 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (6)

  • Chloroquine Resistant Plasmodium Falciparum Malaria
  • Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention
  • Encephalitis due to Toxoplasmosis
  • Malaria
  • Toxoplasmosis
  • Toxoplasmosis associated with acquired immunodeficiency syndrome

Off-label uses (2)

  • Pneumocystis Carinii Pneumonia Prevention
  • Toxoplasmosis Prevention

Contraindications (14)

  • Acute nephropathy
  • Anemia
  • Anemia due to enzyme deficiency
  • Bone marrow depression
  • Deficiency of glucose-6-phosphate dehydrogenase
  • Disease of liver
  • Epilepsy
  • Folic acid deficiency
  • Kidney disease
  • Megaloblastic anemia due to folate deficiency
  • Neutropenic disorder
  • Porphyria
  • Third trimester pregnancy
  • Thrombocytopenic disorder

Mechanism & targets

Mechanism of action (MoA)Dihydrofolate Reductase Inhibitors
Established pharmacologic classDihydrofolate Reductase Inhibitor Antimalarial

Molecular targets (23)

TargetGeneActionActivity
Bifunctional dihydrofolate reductase-thymidylate synthase—inhibitorKi 9.72
Bifunctional dihydrofolate reductase-thymidylate synthase—unknownKi 9.07
Dihydrofolate reductasedfrA17unknownKi 8.92
Dihydrofolate reductasefolAunknownKi 8.92
Muscarinic acetylcholine receptor M1CHRM1unknownKi 8.72
Dihydrofolate reductaseDHFRunknownKi 8.10
Dihydrofolate reductase—unknownKi 8.01
Bifunctional dihydrofolate reductase-thymidylate synthase—unknownKi 7.96
Multidrug and toxin extrusion protein 1SLC47A1inhibitorKi 7.10
Bifunctional dihydrofolate reductase-thymidylate synthase—unknownKi 7.01
Dihydrofolate reductaseDHFRunknownIC50 7.00
Multidrug and toxin extrusion protein 1Slc47a1unknownKi 6.84
Bifunctional dihydrofolate reductase-thymidylate synthase—unknownKi 6.60
Bifunctional dihydrofolate reductase-thymidylate synthase—unknownIC50 6.41
Multidrug and toxin extrusion protein 2Slc47a2inhibitorKi 6.30
Dihydrofolate reductaseDhfrunknownIC50 5.85
Beta-hexosaminidase subunit alphaHEXAunknownIC50 5.51
Solute carrier family 22 member 1Slc22a1unknownKi 5.44
Beta-hexosaminidase subunit betaHEXBunknownIC50 5.35
Dihydrofolate reductaseDFR1unknownIC50 5.30

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1953-01-23FDA—AMEDRA PHARMS

ATC classification

ATC codeTherapeutic hierarchy
P01BD01ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › ANTIMALARIALS › Diaminopyrimidines
P01BD51ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › ANTIMALARIALS › Diaminopyrimidines
P01BF04ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › ANTIMALARIALS › Artemisinin and derivatives, combinations
P01BF09ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › ANTIMALARIALS › Artemisinin and derivatives, combinations

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Pancytopenia176.9
Cerebral toxoplasmosis133.1
Neutropenia97.3
Drug reaction with eosinophilia and systemic symptoms89.6
Urinary tract inflammation85.0
Bone marrow failure77.1
Hepatocellular injury63.3
Pathogen resistance57.7
Immune reconstitution inflammatory syndrome57.3
Toxoplasmosis57.0
Conductive deafness53.6
Hepatitis cholestatic52.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Pyrimethamine is on its molecule page.

Molecular formulaC12H13ClN4
Molecular weight248.71 g/mol
CAS number58-14-0
InChIKeyWKSAUQYGYAYLPV-UHFFFAOYSA-N
PubChem CID4993
CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Pyrimethamine used for?

DrugCentral lists the following indications for Pyrimethamine: Chloroquine Resistant Plasmodium Falciparum Malaria, Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention, Encephalitis due to Toxoplasmosis, Malaria, Toxoplasmosis and Toxoplasmosis associated with acquired immunodeficiency syndrome.

How does Pyrimethamine work?

Pyrimethamine is classified as Dihydrofolate Reductase Inhibitors; its molecular targets in DrugCentral include Bifunctional dihydrofolate reductase-thymidylate synthase (inhibitor), Bifunctional dihydrofolate reductase-thymidylate synthase, dfrA17 and folA.

When was Pyrimethamine first approved?

Pyrimethamine was first approved by the FDA in 1953.

What drug class does Pyrimethamine belong to?

Pyrimethamine is in the Dihydrofolate Reductase Inhibitor Antimalarial class.

What is the chemical formula of Pyrimethamine?

Pyrimethamine has the molecular formula C12H13ClN4 and a molecular weight of 248.71 g/mol.

Browse: all drugs starting with P · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval1953-01-23
AgencyFDA
Targets23
Indications6
FormulaC12H13ClN4
DrugCentral ID2332
Interactive profile